Oct 29, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... 3. Annex II. Amendments to the product information of the nationally ...
Oct 29, 2016 - should be discontinued if there is persistent bleeding and no alternative explanations are identified. Package Leaflet. 2. Warnings and precautions. Cefoperazone - active substance of â may inhibit blood clotting. Serious bleedings,
Oct 29, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... 3. Annex II. Amendments to the product information of the nationally ...
Oct 29, 2016 - Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through). Summary of Product Characteristics. â¢. Section 4.6. Prolonged use of hydromorphone during p
Oct 29, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... 3. Annex II. Amendments to the product information of the nationally ...
Jan 28, 2017 - The primary analysis examined sudden death within seven days of an outpatient prescription for one of ... Package Leaflet. â¢. Section 2.
Sep 2, 2016 - THE WELLCOME FOUNDATION. LTD. GR. Valtrex 250 mg comprimidos revestidos por pelÃcula. SE/H/1041/001. 2966083. LABORATORIOS WELLCOME DE. PORTUGAL LIMITADA. PT. Valtrex 250 mg comprimidos revestidos por pelÃcula. SE/H/1041/001. 3131786.
Mar 11, 2017 - Considering the presented cumulative analysis of cases reporting withdrawal symptoms and drug abuse the ... Package Leaflet. â¢. Section 4 ...
Mar 10, 2018 - Scientific conclusions. Taking into account the PRAC Assessment Report on the PSUR(s) for azithromycin (systemic use formulations), the scientific conclusions are as follows: In view of the increasing understanding on drug-drug interac
